Market Summary
USD211.28+3.29
Market Closed1.58%
RMD Alerts
RMD Stock Price
RMD RSI Chart
RMD Valuation
RMD Price/Sales (Trailing)
RMD Profitability
RMD Fundamentals
RMD Revenue
RMD Earnings
Price Action
52 Week Range
188.66260.79
(Low)(High)
Last 7 days
-3.1%
Last 30 days
-3.3%
Last 90 days
-3.3%
Trailing 12 Months
-14.3%
RMD Financial Health
RMD Investor Care
Peers (Alternatives to ResMed)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 104.1B | 18.4B | 2.26% | 8.00% | 44.16 | 5.64 | 7.84% | 18.25% |
ISRG | 84.2B | 6.2B | -4.47% | -13.27% | 63.66 | 13.53 | 8.97% | -22.43% |
BSX | 69.1B | 12.7B | 0.59% | 12.45% | 99.06 | 5.45 | 6.68% | -32.95% |
BDX | 67.4B | 19.0B | -5.16% | -6.78% | 41.86 | 3.55 | -0.43% | -8.78% |
EW | 49.8B | 5.4B | 2.41% | -25.12% | 32.74 | 9.26 | 2.86% | 1.25% |
| MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 9.34% | 31.15% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.2B | 847.1M | -3.64% | 34.52% | -5.1K | 12.05 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -11.64% | -20.31% | 30.19 | 5.09 | 6.76% | 24.45% |
IRTC | 3.5B | 410.9M | 4.51% | -3.13% | -29.82 | 8.43 | 27.29% | -14.60% |
TNDM | 2.7B | 801.2M | 1.13% | -58.87% | -28.25 | 3.34 | 14.00% | -707.69% |
| SMALL-CAP | ||||||||
SILK | 1.7B | 138.6M | -15.68% | 29.18% | -30.43 | 12.07 | 36.62% | -10.44% |
ATEC | 1.6B | 350.9M | 10.38% | 49.06% | -10.84 | 4.7 | 44.26% | -5.42% |
AVNS | 1.3B | 820.0M | -8.35% | -12.22% | 25.89 | 1.59 | 10.13% | 701.59% |
CSII | 828.4M | 239.8M | 0.30% | 1.49% | -21.88 | 3.45 | -4.74% | -31.15% |
Financials for ResMed
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 3.8% | 3,763 | 3,624 | 3,578 | 3,539 | 3,444 |
| Gross Profit | 3.7% | 2,134 | 2,059 | 2,024 | 1,993 | 1,949 |
| Operating Expenses | 4.2% | 1,089 | 1,045 | 1,024 | 1,006 | 973 |
| S&GA Expenses | 3.5% | 783 | 757 | 739 | 726 | 704 |
| R&D Expenses | 2.9% | 264 | 257 | 254 | 249 | 238 |
| EBITDA | 2.7% | 1,103 | 1,074 | 1,098 | 1,095 | - |
| EBITDA Margin | -1.1% | 0.29* | 0.30* | 0.31* | 0.31* | - |
| Earnings Before Taxes | 3.8% | 1,000 | 963 | 960 | 962 | 953 |
| EBT Margin | -0.1% | 0.27* | 0.27* | 0.27* | 0.27* | - |
| Interest Expenses | -9.4% | -51.09 | -46.70 | -22.31 | -47.81 | -47.45 |
| Net Income | 2.9% | 809 | 786 | 779 | 779 | 522 |
| Net Income Margin | -0.9% | 0.22* | 0.22* | 0.22* | 0.22* | - |
| Free Cahsflow | -27.1% | 237 | 325 | 216 | 364 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 28.9% | 6,676 | 5,178 | 5,096 | 4,905 | 4,735 |
| Current Assets | 14.3% | 2,325 | 2,034 | 1,931 | 1,704 | 1,547 |
| Cash Equivalents | 22.2% | 253 | 207 | 274 | 202 | 194 |
| Inventory | 14.3% | 989 | 865 | 744 | 665 | 592 |
| Net PPE | 7.3% | 523 | 487 | 498 | 513 | 478 |
| Goodwill | 42.7% | 2,767 | 1,939 | 1,936 | 1,946 | 1,951 |
| Liabilities | 68.4% | 2,938 | 1,745 | 1,735 | 1,626 | 1,589 |
| Current Liabilities | 5.8% | 733 | 693 | 689 | 667 | 621 |
| . Short Term Borrowings | -0.1% | 10.00 | 10.00 | 10.00 | 12.00 | 12.00 |
| Long Term Debt | 128.0% | 1,791 | 785 | 765 | 669 | 668 |
| Shareholder's Equity | 8.9% | 3,738 | 3,433 | 3,361 | 3,279 | 3,146 |
| Retained Earnings | 4.3% | 3,920 | 3,760 | 3,614 | 3,480 | 3,363 |
| Additional Paid-In Capital | 0.5% | 1,711 | 1,702 | 1,682 | 1,645 | 1,629 |
| Shares Outstanding | 0.3% | 147 | 146 | 146 | 146 | 146 |
| Float | - | 37,771 | - | - | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -19.8% | 370 | 461 | 351 | 498 | 577 |
| Share Based Compensation | 0.6% | 65.00 | 65.00 | 65.00 | 66.00 | 66.00 |
| Cashflow From Investing | -382.1% | -1,189 | -246 | -229 | -222 | -231 |
| Cashflow From Financing | 437.2% | 888 | -263 | -128 | -299 | -397 |
| Dividend Payments | 1.3% | 252 | 249 | 245 | 241 | 236 |
Risks for RMD
What is the probability of a big loss on RMD?
62.3%
Probability that ResMed stock will be more than 20% underwater in next one year
26.9%
Probability that ResMed stock will be more than 30% underwater in next one year.
0%
Probability that ResMed stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does RMD drawdown profile look like?
Y-axis is the maximum loss one would have experienced if ResMed was unfortunately bought at previous high price.
Drawdowns
Returns for RMD
Cumulative Returns on RMD
18.7%
10-Year Cumulative Returns
21.7%
7-Year Cumulative Returns
17.3%
5-Year Cumulative Returns
12.4%
3-Year Cumulative Returns
What are the long-term rolling returns for RMD?
FIve years rolling returns for ResMed.
Annualized Returns
Which funds bought or sold RMD recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -10.78 | -2,465,170 | 14,034,800 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -48.75 | -15,450,000 | 14,760,000 | 0.02% |
2023-03-10 | MATHER GROUP, LLC. | reduced | -18.74 | -76,340 | 262,660 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -91.91 | -29,338,000 | 2,450,000 | 0.01% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -6.14 | -183,527 | 1,563,470 | 0.10% |
2023-02-28 | Voya Investment Management LLC | reduced | -8.02 | -9,772,390 | 69,622,600 | 0.10% |
2023-02-28 | CYPRESS ASSET MANAGEMENT INC/TX | unchanged | - | -13,228 | 275,772 | 0.10% |
2023-02-28 | Orin Green Financial, LLC | new | - | 557,997 | 557,997 | 0.33% |
2023-02-27 | ST GERMAIN D J CO INC | added | 11.42 | -3,939,640 | 4,362 | -% |
2023-02-24 | National Pension Service | added | 2.63 | -1,144,260 | 50,282,800 | 0.10% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
RMD Alerts
ResMed News
Schedule 13G FIlings of ResMed
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 10, 2023 | wcm investment management, llc | 2.6% | 3,832,642 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 11.63% | 17,028,881 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 9.4% | 13,774,787 | SC 13G/A | |
| Feb 10, 2022 | wcm investment management, llc | 6.21% | 9,046,150 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 11.06% | 16,119,963 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 9.3% | 13,561,224 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.65% | 15,439,844 | SC 13G/A | |
| Feb 10, 2021 | wcm investment management, llc | 6.09% | 8,821,570 | SC 13G/A | |
| Feb 01, 2021 | blackrock inc. | 9.7% | 14,073,568 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 10.98% | 15,790,293 | SC 13G/A |
RMD Fair Value
ResMed fair value in different scenarios
The table shows the Fair Value estimates for ResMed for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 84.10 -60.20% | 105.11 -50.25% | 137.13 -35.10% | 173.47 -17.90% | 201.39 -4.68% |
| Current Inflation | 77.21 -63.46% | 95.03 -55.02% | 121.62 -42.44% | 151.83 -28.14% | 174.96 -17.19% |
| Very High Inflation | 68.73 -67.47% | 82.90 -60.76% | 103.39 -51.06% | 126.78 -39.99% | 144.63 -31.55% |
Historical ResMed Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of ResMed
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 16, 2023 | 4 | Insider Trading | |
| Mar 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 03, 2023 | 144 | Notice of Insider Sale Intent | |
| Feb 22, 2023 | 4 | Insider Trading | |
| Feb 16, 2023 | 4 | Insider Trading | |
| Feb 16, 2023 | 4 | Insider Trading | |
| Feb 14, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | SC 13G/A | Major Ownership Report |
Latest Insider Trading transactions for RMD
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-03 | Ghoshal Kaushik | sold | -220,000 | 220 | -1,000 | president, saas business |
2023-03-03 | PENDARVIS DAVID | sold | -325,035 | 216 | -1,500 | chief administrative officer |
2023-02-17 | Sandercock Brett | sold | -2,152,200 | 215 | -10,000 | chief financial officer |
2023-02-15 | Douglas Robert Andrew | sold | -320,250 | 213 | -1,500 | president and coo |
2023-02-15 | Farrell Michael J. | acquired | 327,788 | 57.76 | 5,675 | chief executive officer |
2023-02-15 | Farrell Michael J. | sold | -1,219,140 | 214 | -5,675 | chief executive officer |
2023-02-13 | Sandercock Brett | sold | -860,000 | 215 | -4,000 | chief financial officer |
2023-02-03 | PENDARVIS DAVID | sold | -336,750 | 224 | -1,500 | chief administrative officer |
2023-02-02 | Drexler Karen | sold | -134,589 | 226 | -594 | - |
2023-01-17 | Farrell Michael J. | sold | -1,273,270 | 224 | -5,675 | chief executive officer |
About ResMed
RMD Income Statement
2022-12-31Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
| Net revenue | $ 1,033,744,000 | $ 894,874,000 | $ 1,984,038,000 | $ 1,798,890,000 |
| Cost of sales (exclusive of amortization shown separately below) | 446,724,000 | 379,325,000 | 849,834,000 | 765,993,000 |
| Amortization of acquired intangible assets | 7,305,000 | 11,231,000 | 13,680,000 | 22,289,000 |
| Total cost of sales | 454,029,000 | 390,556,000 | 863,514,000 | 788,282,000 |
| Gross profit | 579,715,000 | 504,318,000 | 1,120,524,000 | 1,010,608,000 |
| Operating Expenses | ||||
| Selling, general, and administrative | 211,672,000 | 185,362,000 | 404,860,000 | 362,082,000 |
| Research and development | 69,874,000 | 62,507,000 | 133,062,000 | 122,457,000 |
| Amortization of acquired intangible assets | 9,563,000 | 7,738,000 | 17,513,000 | 15,445,000 |
| Acquisition related expenses | 8,412,000 | 0 | 9,157,000 | 0 |
| Total operating expenses | 299,521,000 | 255,607,000 | 564,592,000 | 499,984,000 |
| Income from operations | 280,194,000 | 248,711,000 | 555,932,000 | 510,624,000 |
| Other income (loss), net: | ||||
| Interest (expense) income, net | (10,338,000) | (5,948,000) | (17,472,000) | (11,308,000) |
| Loss attributable to equity method investments (note 5) | (2,826,000) | (1,914,000) | (4,853,000) | (3,300,000) |
| Gain (loss) on equity investments (note 5) | 8,368,000 | (4,404,000) | 5,088,000 | 1,208,000 |
| Other, net | (1,707,000) | 841,000 | (3,211,000) | (1,150,000) |
| Total other income (loss), net | (6,503,000) | (11,425,000) | (20,448,000) | (14,550,000) |
| Income before income taxes | 273,691,000 | 237,286,000 | 535,484,000 | 496,074,000 |
| Income taxes | 48,777,000 | 35,535,000 | 100,092,000 | 90,710,000 |
| Net income | $ 224,914,000 | $ 201,751,000 | $ 435,392,000 | $ 405,364,000 |
| Basic earnings per share (dollars per share) | $ 1.53 | $ 1.38 | $ 2.97 | $ 2.78 |
| Diluted earnings per share (dollars per share) | 1.53 | 1.37 | 2.95 | 2.76 |
| Dividend declared per share (dollars per share) | $ 0.44 | $ 0.42 | $ 1.68 | $ 0.84 |
| Basic shares outstanding (000's) (shares) | 146,704 | 145,990 | 146,568 | 145,835 |
| Diluted shares outstanding (000's) (shares) | 147,405 | 147,040 | 147,367 | 147,044 |
| Total Sleep and Respiratory Care | ||||
| Net revenue | $ 916,981,000 | $ 795,840,000 | $ 1,761,424,000 | $ 1,602,339,000 |
| Cost of sales (exclusive of amortization shown separately below) | 406,303,000 | 343,194,000 | 770,146,000 | 692,876,000 |
| Amortization of acquired intangible assets | 1,343,000 | 1,072,000 | 2,572,000 | 1,972,000 |
| Software as a Service | ||||
| Net revenue | 116,763,000 | 99,034,000 | 222,614,000 | 196,551,000 |
| Cost of sales (exclusive of amortization shown separately below) | 40,421,000 | 36,131,000 | 79,688,000 | 73,117,000 |
| Amortization of acquired intangible assets | $ 5,962,000 | $ 10,159,000 | $ 11,108,000 | $ 20,317,000 |
RMD Balance Sheet
2022-12-31Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Dec. 31, 2022 | Jun. 30, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 253,199 | $ 273,710 |
| Accounts receivable, net of allowances of $27,118 and $23,259 at December 31, 2022 and June 30, 2022, respectively | 672,271 | 575,950 |
| Inventories (note 3) | 988,955 | 743,910 |
| Prepaid expenses and other current assets (note 3) | 410,731 | 337,908 |
| Total current assets | 2,325,156 | 1,931,478 |
| Non-current assets: | ||
| Property, plant and equipment, net (note 3) | 522,745 | 498,181 |
| Operating lease right-of-use assets | 128,222 | 132,314 |
| Goodwill (note 4) | 2,767,179 | 1,936,442 |
| Other intangible assets, net (note 3) | 586,857 | 345,944 |
| Deferred income taxes | 85,783 | 79,746 |
| Prepaid taxes and other non-current assets | 260,162 | 171,748 |
| Total non-current assets | 4,350,948 | 3,164,375 |
| Total assets | 6,676,104 | 5,095,853 |
| Current liabilities: | ||
| Accounts payable | 196,003 | 159,245 |
| Accrued expenses | 312,169 | 344,722 |
| Operating lease liabilities, current | 22,429 | 21,856 |
| Deferred revenue | 133,909 | 108,667 |
| Income taxes payable (note 6) | 58,304 | 44,893 |
| Short-term debt, net (note 8) | 9,900 | 9,916 |
| Total current liabilities | 732,714 | 689,299 |
| Non-current liabilities: | ||
| Deferred revenue | 102,803 | 95,455 |
| Deferred income taxes | 107,540 | 9,714 |
| Operating lease liabilities, non-current | 116,445 | 120,453 |
| Other long-term liabilities | 50,603 | 5,974 |
| Long-term debt, net (note 8) | 1,790,689 | 765,325 |
| Long-term income taxes payable (note 6) | 37,183 | 48,882 |
| Total non-current liabilities | 2,205,263 | 1,045,803 |
| Total liabilities | 2,937,977 | 1,735,102 |
| Commitments and contingencies (note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | 0 | 0 |
| Common stock, $0.004 par value, 350,000,000 shares authorized; 188,737,368 issued and 146,901,134 outstanding at December 31, 2022 and 188,246,955 issued and 146,410,721 outstanding at June 30, 2022 | 588 | 586 |
| Additional paid-in capital | 1,710,766 | 1,682,432 |
| Retained earnings | 3,920,197 | 3,613,736 |
| Treasury stock, at cost, 41,836,234 shares at December 31, 2022 and June 30, 2022 | (1,623,256) | (1,623,256) |
| Accumulated other comprehensive loss | (270,168) | (312,747) |
| Total stockholders’ equity | 3,738,127 | 3,360,751 |
| Total liabilities and stockholders’ equity | $ 6,676,104 | $ 5,095,853 |